GLB-002

· Hangzhou GluBio Pharmaceutical Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for GLB-002, covering 2025-08-19 to 2025-08-19. Get the full timeline:

Most recent: Clinical Trial Update: A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas [Phase 1]